A biotechnology company that isdeveloping treatments for Adrenomyeloneuropathy (AMN), HIV and MultipleSclerosis (MS), has announced today that its recently launched painreliever, Cobroxin, was selected as the "Best New Product" at theEfficient Collaborative Retail Marketing (ECRM) Conference. Cobroxinwas chosen as the award recipient by conference attendees, includingseveral of the leading national retailers.
Nutra Pharma Corp. (OTCBB: NPHC),
"Winning this awardis an exciting achievement for Nutra Pharma, as it reflects thesignificant amount of positive response we have received from retailerswho are looking to offer their customers a safe and effectivealternative to current pain relievers," commented Rik J. Deitsch,Chairman and CEO of Nutra Pharma. "As we begin introducing Cobroxinthrough retailers this fall, we plan to continue our efforts educatingboth retailers and consumers about Cobroxin's unique analgesicproperties, which do not rely on opiates or acetaminophen for its painrelieving effects," he concluded.
Cobroxin is the first OTCpain reliever clinically proven to treat Stage 2 (moderate to severe)chronic pain. The drug, which was developed by Nutra Pharma'swholly-owned drug discovery subsidiary, ReceptoPharm, will be availableas an oral spray (NDC47219-102-52) for treating lower back pain,migraines, neck aches, shoulder pain, cramps and neuralgia and as atopical gel (NDC47219-104-50) for treating repetitive stress,arthritis, and joint pain.
Additional benefits to Cobroxin include:
-- All Natural
-- More Potent than Morphine
-- Long Lasting
Recently,Nutra Pharma announced a licensing agreement that grants XenaCareHoldings (OTCBB: XCHO) ongoing exclusive marketing and distributionrights for Cobroxin within the United States in return for meetingspecific minimum performance requirements. In addition, the Companyalso announced successful submission of final Cobroxin packaging andlabeling to the Food and Drug Administration (FDA), the final steprequired to begin selling Cobroxin.